Dr. John Cush RheumNow
1 year 8 months ago
VA (Veterans) study of 531 RA-ILD (among 9,701 incident RA) vs 68,852 matched controls - finds exposure to fire smoke PM2.5 assoc w/ RA-ILD/aOR 1.98 (but not RA). NOx, ozone, and PM10 assoc w/ seroneg. RA risk (aOR 1.16-1.25) . Pollution increases risk of RA & RA-ILD… https://t.co/AuG4rRtx4r https://t.co/XyHtjrSfhi
Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).
A pilot trial has shown a thrombopoietin receptor agonist, eltrombopag (Promacta), to be effective in connective tissue disease-related (CTD), refractory immune thrombocytopenia (ITP).
Dr. John Cush RheumNow
1 year 8 months ago
Network metanalysis of 9 RCTs, 3699 patients looked at small molecule Rx in #PsA. With ACR 50/70, PASI 75, & HAQ-DI @ wk 12-16, UPA was > ADA in PASI75 (RR 1.2); Deucravacitinib > Otezla at HAQ (RR −0.16) no OTHER SIGNIF differences observed https://t.co/T0eMkXrxQX https://t.co/FCkbuhi1ze
Dr. John Cush RheumNow
1 year 8 months ago
FDA Approves First Generic of GLP-1 Receptor Agonist Victoza (liraglutide injection) to Lower Blood Sugar in Patients with Type 2 Diabetes https://t.co/1BYQFU2PsY https://t.co/jmbS9UDnhI
Dr. John Cush RheumNow
1 year 8 months ago
GLP-1 Agonists Alleviate Knee Osteoarthritis
In October, the NEJM published a randomized clinical trial demonstrating the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1ra) in patients with obesity and knee osteoarthritis.
https://t.co/3ETmyFWpWY https://t.co/wn1QDwKi3R
Dr. John Cush RheumNow
1 year 8 months ago
A Modifiable Vascular Risk in SLE
Atherosclerosis progression was more than 2x as common in younger people with SLE than in healthy controls in a prospective study from Greece.
https://t.co/zGTGin664D https://t.co/ZO9UlIPNIi
Dr. John Cush RheumNow
1 year 8 months ago
U.S. overdose deaths far outpace other countries. In 2023 US drug overdoses >100,000 for 3rd year — a >50% jump since 2019. 2022 rate=324/1 million. High rates attributed to fentanyl, polysubstance use, counterfeit pills, variance in state policies on harm reduction… https://t.co/oHtiMytdtR https://t.co/DLFPYEkdRC
Dr. John Cush RheumNow
1 year 8 months ago
Online, lifestyle intervention program shown to have positive long-term effects in 264 patients w/ Inflam Arthritis, OA & FM , even after 2-yrs. Prg focused on nutrition, exercise, relaxation & sleep. Signif reductions in Wt, BMI, and PRO's (pain, Am stiff, fatigue)… https://t.co/vghObYPnvW https://t.co/ZSdFPWel57
Dr. John Cush RheumNow
1 year 8 months ago
Leeds study of 19 pts at-risk for RA (ACPA+ & arthralgia) finds low-diversity gut microbiome & in the 10 mos preceding the transition to RA, microbiome becomes more unstable w/ accumulation of Prevotellaceae, particularly Prevotella copri https://t.co/Va9Z0NWHj9 https://t.co/ciM7QtEF5S
Dr. John Cush RheumNow
1 year 8 months ago
Study of 1032 adults > 50 yrs on dialysis compared denosumab vs or oral bisphosphonates. 3 yr results showed compared with oral bisphosphonates, denosumab lowered the risk for fractures by 45% and increased the risk for MACE by 36% https://t.co/aogIFBrccy https://t.co/cnlxt5OEjj
Dr. John Cush RheumNow
1 year 8 months ago
Anti-Zoster Drug Prevents Shingles in Lupus Patients on Anifrolumab
The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with SLE under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential… https://t.co/I3u8tK5EMq https://t.co/VItPWtrPUA
Dr. John Cush RheumNow
1 year 8 months ago
In #RA, Higher levels of ESR and CRP, but not DAS28, joint counts or global assessments, were significantly associated with the risk of incident ILD in RA. German biologics (RABBIT) registry study compared 139 RA-ILD vs vs 686 controls. https://t.co/IB7aS6IKgT https://t.co/0zN5N7w65l
Dr. John Cush RheumNow
1 year 8 months ago
Steroids and Infection
https://t.co/J8OU6I9410 https://t.co/JwpSrS4ouI

